Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.
发布日期：2011-07-13 17:28 文章来源：互联网
分享到：
点击次数：
Background: Addition of cetuximab (cet) to first-line chemotherapy (CT) was shown to significantly improve clinical benefit in patients (pts) with KRAS wild-type (wt) mCRC. Pts with KRAS codon 12 or 13 mutations are excluded from cet treatment. Studies suggest that not all KRAS mutations are equivalent in their biological effects. We investigated the influence of the KRAS codon 13 mutation G13D on clinical outcome compared with pts with other KRAS tumor mutations or KRAS wt tumors in a pooled analysis of pts from the CRYSTAL and OPUS studies. Methods: Variation of the treatment effect by KRAS mutation status, and the effect of KRAS mutation status within each treatment group for response, progression-free (PFS) and overall survival (OS) was investigated. Results: There were 689 pts in each treatment arm: 447 vs 398 pts had KRAS wt tumors, 41 vs 42 pts had KRAS G13D mutant tumors and 201 vs 249 pts had tumors with other KRAS mutations, for the CT and CTcet arms, respectively. Heterogeneous treatment effects were seen for all endpoints across the mutation types with significant treatment interaction by KRAS mutation status for response (p0.0001), PFS (p0.0001) and OS (p0.0219). Compared with pts with KRAS wt tumors those with G13D mutations had a similar relative treatment effect but at a much lower effect level (Table). Conclusions: These observations suggest a heterogeneous treatment effect according to tumor KRAS mutation status. Pts with KRAS G13D mutant mCRC appear to benefit from the addition of cet to first-line CT. Further prospectively generated clinical investigations are necessary to confirm these data.
编辑: xy
以下网友留言只代表网友个人观点，不代表网站观点
